<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185012</url>
  </required_header>
  <id_info>
    <org_study_id>NAPPREB</org_study_id>
    <nct_id>NCT04185012</nct_id>
  </id_info>
  <brief_title>NAsal Polyps: Inflammatory &amp; Molecular Phenotyping of Responders to Benralizumab</brief_title>
  <acronym>NAPPREB</acronym>
  <official_title>NAsal Polyps: Inflammatory &amp; Molecular Phenotyping of Responders to Benralizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humanitas Clinical and Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Humanitas Clinical and Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and rationale:&#xD;
&#xD;
      Phase III-b study.&#xD;
&#xD;
      Population and patient selection criteria: Adult patients with Chronic Rhinosinusitis with&#xD;
      Nasal Polyps (allergic and non-allergic) requiring at least 1000 mg oral prednisone over the&#xD;
      previous twelve months to control symptoms of rhinosinusitis, and with:&#xD;
&#xD;
        -  Nasal polyps score (Meltzer et al.) â‰¥ 5&#xD;
&#xD;
        -  Symptoms VAS scores (for nasal obstruction, hyposmia, post-nasal drip, sneezing,&#xD;
           rhinorrea; 0-10 for each symptom) &gt; 24 Sample size: 20 subjects.&#xD;
&#xD;
      Study design and study duration:&#xD;
&#xD;
      This is a pilot, prospective, double-blind placebo-controlled (DBPC) phase III-b trial with&#xD;
      Benralizumab 30 mg administered subcutaneously every 4 weeks for the first 3 doses and then&#xD;
      every 8 weeks, for a treatment-period of 16 weeks (followed up at 32 and 52 weeks) in&#xD;
      patients with chronic rhinosinusinusitis with nasal polyps (CRSwNP).&#xD;
&#xD;
      Description of study treatment/product/intervention: Benralizumab, 30 mg subcutaneously every&#xD;
      4 week for the first 3 doses, and then every 8 weeks.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  Primary objective: To assess the clinical efficacy of Benralizumab on CRSwNP at week 24&#xD;
           (vs baseline) after the beginning of treatment, and to correlate the presence of&#xD;
           baseline biomarkers with nasal polyp (NP) score improvement, in order to identify any&#xD;
           possible predictive biomarker of response to Benralizumab.&#xD;
&#xD;
        -  Secondary objective: In the follow up phase we will monitor all the biomarkers at 32 and&#xD;
           52 weeks , this monitoring will ascertain if any of those will predict relapse of nasal&#xD;
           polyps and consequently when Benralizumab treatment has to be reinstalled.&#xD;
&#xD;
        -  Safety objective: To evaluate the safety and tolerability of Benralizumab in patients&#xD;
           with CRSwNP&#xD;
&#xD;
      Statistical methods, data analysis: Descriptive analysis of all collected variables at all&#xD;
      time-points will be performed. Patients will be classified into &quot;responders&quot; and &quot;non&#xD;
      responders&quot;, for primary endopoint variable. Continuous variables will be evaluated with the&#xD;
      normality test of Kolmogorov-Smirnov and compared with ANOVA or the Mann-Whitney test,&#xD;
      depending on the normality of distribution. Categorical variables will be compared using&#xD;
      Fisher's exact test.&#xD;
&#xD;
      Ethical considerations: The study will be performed in accordance with ethical principles&#xD;
      that have their origin in the Declaration of Helsinki and are consistent with ICH/Good&#xD;
      Clinical Practice, applicable regulatory requirements and the Sponsor policy on Bioethics and&#xD;
      Human Biological Samples.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, placebo-controlled clinical trial. Patients will be divided in two arms with 1:1 randomization to Treatment or Placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Randomization will occur by assigning a unique sequential study code to a balanced number of randomly assorted treatment vials.&#xD;
An online open source randomization software will be used to assign treatment groups, and this will be done by an external person from those who will follow and treat the patients.&#xD;
Patients randomization will be blinded to the patients themselves and to all the personnel that will have contact with them during the trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Significant reduction of the Nasal polyps Score (range: 0-8; higher values mean larger nasal polyps size)</measure>
    <time_frame>at week 24 (vs baseline)</time_frame>
    <description>score reduction of 1.5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in Lund-MacKay Score (range: 0-24; higher values mean larger nasal polyps extension)</measure>
    <time_frame>at week 24 (vs baseline)</time_frame>
    <description>&gt;50% of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Sino-Nasal Outcome Test (SNOT-22; range: 0-110; higher values mean poorer disease-related quality of life)</measure>
    <time_frame>at week 24 (vs baseline)</time_frame>
    <description>&gt;40% of baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of smell Visual Analogue Scale (VAS; range: 0-10; higher values mean worse smell)</measure>
    <time_frame>at week 24 (vs baseline)</time_frame>
    <description>&gt;50% of baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Benralizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab 30 mg administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks, for a treatment-period of 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab</intervention_name>
    <description>Benralizumab 30 mg administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period</description>
    <arm_group_label>Benralizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously Q4W for the first 3 doses and then Q8W, for a 16 weeks treatment-period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult patients with Chronic Rhinosinusitis with Nasal Polyps (allergic and non-allergic)&#xD;
        requiring at least 1000 mg oral prednisone over the previous twelve months to control&#xD;
        symptoms of rhinosinusitis, and with:&#xD;
&#xD;
          -  Nasal polyps score (Meltzer et al.) &gt; 5&#xD;
&#xD;
          -  Symptoms VAS scores (for nasal obstruction, hyposmia, post-nasal drip, sneezing,&#xD;
             rhinorrea; 0-10 for each symptom) &gt; 24&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt; 18 years age&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Biologic therapy in the past 6 months (or at least a period corresponding to 5&#xD;
             half-life of used drugs) (eg: omalizumab, mepolizumab, reslizumab, dupilumab)&#xD;
&#xD;
          -  Previous treatment with Benralizumab&#xD;
&#xD;
          -  Known hypersensitivity to benralizumab or any of its excipients&#xD;
&#xD;
          -  Immunosuppression other than oral steroids in the past 3 months&#xD;
&#xD;
          -  Allergen immunotherapy in the past 6 months&#xD;
&#xD;
          -  Serious life threatening cardiopulmonary disorders&#xD;
&#xD;
          -  Systemic immunologic disorder in the last 12 months&#xD;
&#xD;
          -  Positive history for malignant tumors ever in patient's life&#xD;
&#xD;
          -  Patients with conditions or concomitant diseases making them non evaluable at visit 1&#xD;
             or for the primary efficacy endpoint:&#xD;
&#xD;
               1. Ongoing rhinitis medicamentosa&#xD;
&#xD;
               2. Nasal septal deviation occluding at least one nostril&#xD;
&#xD;
               3. Acute sinusitis, nasal infection, upper respiratory infections&#xD;
&#xD;
               4. Radiologic suspicion or confirmed invasive or expansive fungal rhinosinusitis&#xD;
&#xD;
               5. Eosinophilic Granulomatosis with Polyangiitis (previously named Churg-Strauss&#xD;
                  Syndrome)&#xD;
&#xD;
               6. Granulomatosis with Polyangiitis (previously named Wegener's granulomatosis)&#xD;
&#xD;
               7. Young's Syndrome&#xD;
&#xD;
               8. Kartagener's Syndrome&#xD;
&#xD;
               9. all ciliary dyskinesia&#xD;
&#xD;
              10. Cystic Fibrosis&#xD;
&#xD;
          -  Systemic corticosteroid treatment for other chronic conditions (i.e.: autoimmune&#xD;
             disorders, tumors,â€¦.)&#xD;
&#xD;
          -  Evidence of active systemic immunedepression (i.e..: primary or secondary&#xD;
             immunodeficiency)&#xD;
&#xD;
          -  Patients with severe asthma, defined according to ERS/ATS definition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giorgio Walter Canonica, MD</last_name>
    <phone>+390288247013</phone>
    <email>giorgio_walter.canonica@hunimed.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Heffler, MD, PhD</last_name>
    <phone>+390288247013</phone>
    <email>enrico.heffler@hunimed.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Humanitas Clinical and Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Walter Canonica, MD</last_name>
      <phone>+390288247013</phone>
      <email>giorgio_walter.canonica@hunimed.eu</email>
    </contact>
    <contact_backup>
      <last_name>Enrico Heffler, MD, PhD</last_name>
      <phone>+390288247013</phone>
      <email>enrico.heffler@hunimed.eu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benralizumab</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Eosinophils</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

